← Back to Search

Digital Reminiscence Therapy for Dementia

N/A

Recruiting

Led By Silvia Orsulic-Jeras, MA

Research Sponsored by Benjamin Rose Institute on Aging

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have a Dementia diagnosis

Must be at least 55 years of Age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediately post-training

Awards & highlights

Study Summary

This trial will test whether LifeBio Memory is an effective intervention for people with dementia.

Who is the study for?

This trial is for English-speaking individuals aged 55 or older with dementia, living in a participating care facility. They must have at least a score of 15 on the Mini Mental State Examination to join. Caregivers eligible must work within these facilities and provide their own transport for interviews.Check my eligibility

What is being tested?

The study tests LifeBio Memory, a digital platform designed to help people with dementia by using machine learning to turn speech into text and create life stories, aiming to improve communication between residents and their caregivers.See study design

What are the potential side effects?

Since LifeBio Memory is a non-pharmacological intervention focusing on reminiscence therapy through conversation and memory elicitation, it does not involve medication; therefore, traditional drug side effects are not expected.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with dementia.

Select...

I am 55 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ after intervention (4 weeks from baseline)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~after intervention (4 weeks from baseline)

This trial's timeline: 3 weeks for screening, Varies for treatment, and after intervention (4 weeks from baseline) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adherence to LifeBio Memory Treatment Protocol

Change in Attitudes towards Residents Scale from Baseline

Change in Center for Epidemiological Studies Depression Scale (CES-D) from Baseline

+11 more

Secondary outcome measures

Change in Adequate Knowledge of Care Preferences from Baseline

Change in Mini Mental Status Examination (MMSE) from Baseline

Change in Understanding of Resident's Life Story from Baseline

+1 more

Other outcome measures

Accuracy of LifeBio Memory Technology

Length of Time Staff Spend on LifeBio Memory Training

Level of Staff Difficulty with LifeBio Memory Training

+4 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: StaffExperimental Treatment1 Intervention

Staff will be trained in the platform, and complete life story interviews with residents at their facilities. Upon completion of training, staff will complete surveys regarding it's effectiveness and utility, and following the completion of the interview, the resident's life story books, summary materials, and staff tools will be delivered four weeks later. Life story materials are meant to assist staff in providing more personalized care and a mechanism for residents to feel more deeply understood.

Group II: ResidentsExperimental Treatment1 Intervention

Residents will be screened for their cognitive status and compete interviews with a researcher prior to participation in the life story interview. Residents will then be interviewed again at T3 about four weeks after the life story books, summaries, and staff materials have been delivered.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Benjamin Rose Institute on AgingLead Sponsor

4 Previous Clinical Trials

2,432 Total Patients Enrolled

2 Trials studying Dementia

2,372 Patients Enrolled for Dementia

Silvia Orsulic-Jeras, MAPrincipal InvestigatorBenjamin Rose Institute on Aging

Media Library

LifeBio Memory Clinical Trial Eligibility Overview. Trial Name: NCT04769466 — N/A

Dementia Research Study Groups: Residents, Staff

Dementia Clinical Trial 2023: LifeBio Memory Highlights & Side Effects. Trial Name: NCT04769466 — N/A

LifeBio Memory 2023 Treatment Timeline for Medical Study. Trial Name: NCT04769466 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment canvassing for study participants aged 55 and above?

"The cut-off for participation in this study is 112 years old, with those between 18 and 65 being the primary enrollment focus. There are also 29 trials geared towards minors and 505 studies that target seniors."

Answered by AI

What primary goals does this research seek to accomplish?

"The primary aim of this trial will span from its Baseline to the 4-week point post-intervention: To measure any changes in Dyadic Relationship Strain (DRS) - Staff. Secondary outcomes include Length of Life Story Interview, Change in Mini Mental Status Examination (MMSE), and Change in Adequate Knowledge of Care Preferences all compared to their pre-intervention values."

Answered by AI

Are there any opportunities for people to participate in this experiment at present?

"According to the most recent data available on clinicaltrials.gov, this medical trial is currently enrolling participants. The initial advertisement of this study was released on March 22nd 2022 with some minor changes as recently as March 24th 2022."

Answered by AI

What is the current capacity for participants in this medical trial?

"Affirmative, clinicaltrials.gov corroborates that this trial is currently recruitment participants. It was originally published on March 22nd 2022 and revised on the 24th of the same month. 302 individuals need to be recruited from 1 site for completion of the clinical study."

Answered by AI